134 related articles for article (PubMed ID: 34511443)
1. [DRUG CORRECTION OF THE STRUCTURAL AND FUNCTIONAL STATUS OF BONE TISSUE IN PATIENTS WITH FIBROUS DYSPLASIA].
Guk Y; Zyma A; Kincha-Polishchuk T; Chewerda A; Skuratov O
Georgian Med News; 2021; (316-317):46-52. PubMed ID: 34511443
[TBL] [Abstract][Full Text] [Related]
2. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
[TBL] [Abstract][Full Text] [Related]
4. Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.
Florenzano P; Pan KS; Brown SM; Paul SM; Kushner H; Guthrie LC; de Castro LF; Collins MT; Boyce AM
J Bone Miner Res; 2019 Apr; 34(4):653-660. PubMed ID: 30645769
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates for the treatment of fibrous dysplasia of bone.
Chapurlat R; Legrand MA
Bone; 2021 Feb; 143():115784. PubMed ID: 33276154
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate therapy for fibrous dysplasia.
DiMeglio LA
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():440-5. PubMed ID: 17982393
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: The randomized double-blind placebo-controlled TOCIDYS trial.
Chapurlat R; Gensburger D; Trolliet C; Rouanet S; Mehsen-Cetre N; Orcel P
Bone; 2022 Apr; 157():116343. PubMed ID: 35104665
[TBL] [Abstract][Full Text] [Related]
8. Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience.
Valadares LP; de Araújo Ferreira BS; da Cunha BM; Moreira LA; Batista FGA; da Fonseca Hottz C; Magalhães GGR
Arch Endocrinol Metab; 2022 Apr; 66(2):247-255. PubMed ID: 35420267
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Chapurlat RD; Delmas PD; Liens D; Meunier PJ
J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis.
Bertin H; Moussa MS; Komarova S
Rev Endocr Metab Disord; 2023 Dec; 24(6):1103-1119. PubMed ID: 37632645
[TBL] [Abstract][Full Text] [Related]
11. Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.
Rotman M; Hamdy NAT; Appelman-Dijkstra NM
Br J Clin Pharmacol; 2019 Jun; 85(6):1169-1179. PubMed ID: 30471134
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate therapy in fibrous dysplasia.
Lane JM; Khan SN; O'Connor WJ; Nydick M; Hommen JP; Schneider R; Tomin E; Brand J; Curtin J
Clin Orthop Relat Res; 2001 Jan; (382):6-12. PubMed ID: 11154006
[TBL] [Abstract][Full Text] [Related]
13. Medical therapy in adults with fibrous dysplasia of bone.
Chapurlat RD
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P114-9. PubMed ID: 17228999
[TBL] [Abstract][Full Text] [Related]
14. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
Chapurlat R; Meunier PJ
Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate treatment in craniofacial fibrous dysplasia--a case report and review of the literature.
Mäkitie AA; Törnwall J; Mäkitie O
Clin Rheumatol; 2008 Jun; 27(6):809-12. PubMed ID: 18247080
[TBL] [Abstract][Full Text] [Related]
16. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
Lala R; Matarazzo P; Bertelloni S; Buzi F; Rigon F; de Sanctis C
Acta Paediatr; 2000 Feb; 89(2):188-93. PubMed ID: 10709889
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
[TBL] [Abstract][Full Text] [Related]
18. Fibrous dysplasia of bone and McCune-Albright syndrome.
Chapurlat RD; Orcel P
Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):55-69. PubMed ID: 18328981
[TBL] [Abstract][Full Text] [Related]
19. Denosumab Use in Adults With Fibrous Dysplasia: Case Reports and Review of the Literature.
Hung C; Shibli-Rahhal A
Endocr Pract; 2022 Nov; 28(11):1196-1201. PubMed ID: 35952985
[TBL] [Abstract][Full Text] [Related]
20. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
Pfeilschifter J; Ziegler R
Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
